A Systems Toxicology Approach for the Prediction of Kidney Toxicity and Its Mechanisms In Vitro.

Journal: Toxicological sciences : an official journal of the Society of Toxicology
PMID:

Abstract

The failure to predict kidney toxicity of new chemical entities early in the development process before they reach humans remains a critical issue. Here, we used primary human kidney cells and applied a systems biology approach that combines multidimensional datasets and machine learning to identify biomarkers that not only predict nephrotoxic compounds but also provide hints toward their mechanism of toxicity. Gene expression and high-content imaging-derived phenotypical data from 46 diverse kidney toxicants were analyzed using Random Forest machine learning. Imaging features capturing changes in cell morphology and nucleus texture along with mRNA levels of HMOX1 and SQSTM1 were identified as the most powerful predictors of toxicity. These biomarkers were validated by their ability to accurately predict kidney toxicity of four out of six candidate therapeutics that exhibited toxicity only in late stage preclinical/clinical studies. Network analysis of similarities in toxic phenotypes was performed based on live-cell high-content image analysis at seven time points. Using compounds with known mechanism as reference, we could infer potential mechanisms of toxicity of candidate therapeutics. In summary, we report an approach to generate a multidimensional biomarker panel for mechanistic de-risking and prediction of kidney toxicity in in vitro for new therapeutic candidates and chemical entities.

Authors

  • Susanne Ramm
    Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical SchoolBoston, MA.
  • Petar Todorov
    Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical SchoolBoston, MA.
  • Vidya Chandrasekaran
    Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical SchoolBoston, MA.
  • Anders Dohlman
    Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical SchoolBoston, MA.
  • Maria B Monteiro
    Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical SchoolBoston, MA.
  • Mira Pavkovic
    Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical SchoolBoston, MA.
  • Jeremy Muhlich
    Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical SchoolBoston, MA.
  • Harish Shankaran
    Safety and ADME Modeling, Drug Safety, and Metabolism, IMED Biotech Unit, AstraZeneca, Waltham MA.
  • William W Chen
    Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical SchoolBoston, MA.
  • Jerome T Mettetal
    Safety and ADME Modeling, Drug Safety, and Metabolism, IMED Biotech Unit, AstraZeneca, Waltham MA.
  • Vishal S Vaidya
    Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical SchoolBoston, MA.